ASH 2018 | Camidanlumab tesirine for R/R non-Hodgkin or Hodgkin lymphomas

Graham Collins

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the Phase I study (NCT02432235) evaluating the safety and efficacy of camidanlumab tesirine (Cami-T or ADCT-301), an antibody-drug conjugate, in patients with relapsed/refractory non-Hodgkin or Hodgkin lymphomas. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Collins discusses the promising results from this study, before stressing the need to find the optimal dose; maximizing efficacy, but minimizing the toxicity.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter